A Delphi expert consensus panel proposed that fulfilling ≥1 of the '5-2-1 criteria' (≥five-times daily oral levodopa use, ≥two daily hours with 'Off' symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson's disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD - a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) - is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa-carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.
Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE / Aldred, J; Anca-Herschkovitsch, M; Antonini, A; Bajenaru, O; Bergmann, L; Bourgeois, P; Cubo, E; Davis, Tl; Iansek, R; Kovács, N; Kukreja, P; Onuk, K; Pontieri, Fe; Robieson, W; Siddiqui, Ms; Simu, M; Standaert, Dg; Chaudhuri, Kr.. - In: NEURODEGENERATIVE DISEASE MANAGEMENT. - ISSN 1758-2024. - 10:5(2020), pp. 309-323. [10.2217/nmt-2020-0021]
Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE
Antonini A;Pontieri FE;
2020
Abstract
A Delphi expert consensus panel proposed that fulfilling ≥1 of the '5-2-1 criteria' (≥five-times daily oral levodopa use, ≥two daily hours with 'Off' symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson's disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD - a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) - is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa-carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.| File | Dimensione | Formato | |
|---|---|---|---|
|
Aldred_Application_2020.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.84 MB
Formato
Adobe PDF
|
1.84 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
